MARKET WIRE NEWS

Givaudan: On The Cusp Of Becoming A Dividend Aristocrat

Source: SeekingAlpha

2025-02-07 05:32:40 ET

Summary

  • Givaudan's fiscal year 2024 results were strong, with 12.3% like-for-like sales growth and a 22.1% increase in net income, despite currency headwinds.
  • The company maintains a robust competitive moat through heavy R&D investment, a strong patent portfolio, and leveraging generative AI for innovation.
  • GVDBF's valuation remains high with a P/E ratio above 30x, but its solid balance sheet and consistent dividend growth offer stability.
  • Despite impressive performance and innovation, the stock is still a 'Hold' due to elevated valuation and risks like potential tariff impacts and price-fixing allegations.

Swiss company Givaudan (GVDBF) (GVDNY) has been on our radar for some time, but each time we look at it, we conclude it is just too expensive. We appreciate its strong competitive moat, leading innovation, and resilient business model. Still, the valuation still matters, and that is why we have been of the opinion that shares were a "Hold". With the company recently announcing results for fiscal year 2024, we believe this a good time to reassess the situation, especially given the stock's underperformance compared to the S&P 500 Index ( SP500 ) since we last covered the company about six months ago....

Read the full article on Seeking Alpha

For further details see:

Givaudan: On The Cusp Of Becoming A Dividend Aristocrat
Novozymes A/S ADR

NASDAQ: NVZMY

NVZMY Trading

0.83% G/L:

$54.55 Last:

27,606 Volume:

$54.70 Open:

mwn-ir Ad 300

NVZMY Latest News

NVZMY Stock Data

$25,349,429,542
407,732,498
N/A
6
N/A
Chemicals
Materials
DK
Lyngby

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App